Imrecoxib
Imrecoxib was approved by China Food and Drug Administration (CFDA) on May 20, 2011. It was developed and marketed as 恒扬® by HengRui Pharmaceuticals.
Imrecoxib is a selective COX-2 inhibitor indicated for treatment of osteoarthritis.
恒扬® is available as tablet for oral use, containing 100 mg of free Imrecoxib, and the recommend dose is 100 mg twice daily.
General Information
Update Date：2016-03-14
- Drug Name：
- Imrecoxib
- Research Code：
- BAP-909
- Trade Name：
- 恒扬®
- MOA：
- Selective cyclooxygenase-2 (COX-2) inhibitor
- Indication：
- Osteoarthritis (OA)
- Status：
- Approved
- Company：
- HengRui (Originator)
- Sales：
- ATC Code：
Approved Countries or Area
Update Date：2015-07-29
| Approval Date | Approval Type | Trade Name | Indication | Dosage Form | Strength | Company | Review Classification |
|---|---|---|---|---|---|---|---|
| 2011-05-20 | Marketing approval | 恒扬 | Osteoarthritis (OA) | Tablet, Film coated | 100 mg | HengRui |
Chemical Structure
Update Date：2015-08-27
|
Molecular Weight | 369.48 | ||||||||||||
| Formula | C21H23NO3S | |||||||||||||
| CAS No. | 395683-14-4 (Imrecoxib); | |||||||||||||
| Chemical Name | 4-(4-(methylsulfonyl)phenyl)-1-propyl-3-(p-tolyl)-1H-pyrrol-2(5H)-one | |||||||||||||
| Imrecoxib （Free Acid/Base）Parameters： | ||||||||||||||
|
||||||||||||||
| *：Calculated by ACD/Labs software V11.02. | ||||||||||||||
Related Patents
Update Date：2015-08-31
Synthesis & Impurities
Update Date：2015-10-16
